Colorectal carcinomas with high microsatellite instability: Defining a distinct immunologic and molecular entity with respect to prognostic markers

被引:68
作者
Edmonston, TB
Cuesta, KH
Burkholder, S
Barusevicius, A
Rose, D
Kovatich, AJ
Boman, B
Fry, R
Fishel, R
Palazzo, JP
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Dept Colorectal Surg, Philadelphia, PA 19107 USA
[3] Thomas Jefferson Univ, Jefferson Med Coll, Div Med Genet, Philadelphia, PA 19107 USA
[4] Thomas Jefferson Univ, Jefferson Med Coll, Div Oncol, Philadelphia, PA 19107 USA
[5] Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA
[6] Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Philadelphia, PA 19107 USA
关键词
colorectal cancer; microsatellite instability; cell cycle proteins; prognosis;
D O I
10.1053/hupa.2000.20383
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Molecular analysis of hereditary nonpolyposis colorectal carcinomas (HNPCC) has identified DNA mismatch repair deficiencies with resulting microsatellite instability (MSI) as a pathway of carcinogenesis that appears to be relevant for prognosis, treatment, and possibly prevention. In this study, expression of cell cycle proteins and other known prognostic markers is correlated with the microsatellite status of colorectal cancers (CRC). One hundred consecutive cases from the CRC Registry at Thomas Jefferson University were analyzed for MSI. Immunohistochemistry was performed for the mismatch repair proteins hMLH1 and hMSH2, tumor suppressor p53, apoptosis inhibitor bcl-2, cell cycle proteins p21(WAF1/CIP1), and p27 and the proliferation markers Ki-67 and topoisomerase II. High MSI (MSI-H) is significantly correlated with loss of either hMLH1 or hMSH2, presence of bcl-2, and absence of p53. p21(WAF1/CIP1) is positive in all tumors with MSI-H. Previous findings of a lower proliferation rate were confirmed with a topoisomerase II stain. Microsatellite stable (MSS) tumors generally express both MSH2 and MLH1. Other highly significant differences are positive p53 in 56% of MSS cases and negative bcl-2 in 98% of MSS cases. p27 expression is found in approximately 50% of all CRCs irrespective of the microsatellite status. MSI-H tumors follow the mutator pathway, with loss of expression of one mismatch repair protein, wild-type p53, lower proliferation, and positivity for p(21WAF1/CTP1). MSS tumors follow the suppressor pathway, characterized by p53 overexpression, higher proliferation, and absence of bcl-2 expression; p21(WAF1/CIP1) expression can be variable. These data provide a molecular basis for the clinical observation that patients with HNPCC appear to have a more favorable prognosis. Copyright (C) 2000 by W.B. Saunders Company.
引用
收藏
页码:1506 / 1514
页数:9
相关论文
共 45 条
[1]   Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome [J].
Aarnio, M ;
Mecklin, JP ;
Aaltonen, LA ;
NystromLahti, M ;
Jarvinen, HJ .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (06) :430-433
[2]   EVALUATION OF 6 ANTIBODIES FOR IMMUNOHISTOCHEMISTRY OF MUTANT P53 GENE-PRODUCT IN ARCHIVAL COLORECTAL NEOPLASMS [J].
BAAS, IO ;
MULDER, JWR ;
OFFERHAUS, GJA ;
VOGELSTEIN, B ;
HAMILTON, SR .
JOURNAL OF PATHOLOGY, 1994, 172 (01) :5-12
[3]   The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death [J].
Basu, A ;
Haldar, S .
MOLECULAR HUMAN REPRODUCTION, 1998, 4 (12) :1099-1109
[4]   p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases [J].
Belluco, C ;
Guillem, JG ;
Kemeny, N ;
Huang, Y ;
Klimstra, D ;
Berger, MF ;
Cohen, AM .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2696-2701
[5]  
Bocker T, 1996, J PATHOL, V179, P15
[6]  
BOCKER T, 1999, BBA-REV CANCER, V1423, P10
[7]  
Boland CR, 1998, CANCER RES, V58, P5248
[8]  
Bubb VJ, 1996, ONCOGENE, V12, P2641
[9]  
Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO
[10]  
2-2